VERVE-102 · HEART-3
Lilly's Phase 2 plan is distinct from the positive Heart-2 Phase 1b data already disclosed. The registry supplies HEART-3's exact protocol; no result date is promised. VERVE-102 — phase 2 study in Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia. NCT07839936 lists Percent Change from Baseline in LDL-C as a primary outcome (Baseline, Day 90). Registry status: not yet recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2028-08 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Phase 2 monitor — result date unconfirmed
Potential outcome market
Will VERVE-102 meet the prespecified primary endpoint in NCT07839936 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.